These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 17351110)

  • 1. A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia.
    Harousseau JL; Lancet JE; Reiffers J; Lowenberg B; Thomas X; Huguet F; Fenaux P; Zhang S; Rackoff W; De Porre P; Stone R;
    Blood; 2007 Jun; 109(12):5151-6. PubMed ID: 17351110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome.
    Jabbour E; Kantarjian H; Ravandi F; Garcia-Manero G; Estrov Z; Verstovsek S; O'Brien S; Faderl S; Thomas DA; Wright JJ; Cortes J
    Cancer; 2011 Mar; 117(6):1236-44. PubMed ID: 20960519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features.
    Karp JE; Smith BD; Gojo I; Lancet JE; Greer J; Klein M; Morris L; Levis MJ; Gore SD; Wright JJ; Garrett-Mayer E
    Clin Cancer Res; 2008 May; 14(10):3077-82. PubMed ID: 18483374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432.
    Erba HP; Othus M; Walter RB; Kirschbaum MH; Tallman MS; Larson RA; Slovak ML; Kopecky KJ; Gundacker HM; Appelbaum FR
    Leuk Res; 2014 Mar; 38(3):329-33. PubMed ID: 24411921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia.
    Lancet JE; Gojo I; Gotlib J; Feldman EJ; Greer J; Liesveld JL; Bruzek LM; Morris L; Park Y; Adjei AA; Kaufmann SH; Garrett-Mayer E; Greenberg PL; Wright JJ; Karp JE
    Blood; 2007 Feb; 109(4):1387-94. PubMed ID: 17082323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial.
    Kern W; Haferlach T; Schoch C; Loffler H; Gassmann W; Heinecke A; Sauerland MC; Berdel W; Buchner T; Hiddemann W
    Blood; 2003 Jan; 101(1):64-70. PubMed ID: 12393605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage therapy in refractory acute myeloid leukemia: prediction of outcome based on analysis of prognostic factors.
    Tavernier E; Le QH; Elhamri M; Thomas X
    Leuk Res; 2003 Mar; 27(3):205-14. PubMed ID: 12537972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas.
    Widemann BC; Salzer WL; Arceci RJ; Blaney SM; Fox E; End D; Gillespie A; Whitcomb P; Palumbo JS; Pitney A; Jayaprakash N; Zannikos P; Balis FM
    J Clin Oncol; 2006 Jan; 24(3):507-16. PubMed ID: 16421428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide.
    Karp JE; Flatten K; Feldman EJ; Greer JM; Loegering DA; Ricklis RM; Morris LE; Ritchie E; Smith BD; Ironside V; Talbott T; Roboz G; Le SB; Meng XW; Schneider PA; Dai NT; Adjei AA; Gore SD; Levis MJ; Wright JJ; Garrett-Mayer E; Kaufmann SH
    Blood; 2009 May; 113(20):4841-52. PubMed ID: 19109557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed/refractory peripheral T-cell lymphoma.
    Witzig T; Sokol L; Kim WS; de la Cruz Vicente F; Martín García-Sancho A; Advani R; Roncero Vidal JM; de Oña Navarrete R; Marín-Niebla A; Rodriguez Izquierdo A; Terol MJ; Domingo-Domenech E; Saunders A; Bendris N; Mackey J; Leoni M; Foss F
    Blood Adv; 2024 Sep; 8(17):4581-4592. PubMed ID: 38991123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia.
    Roboz GJ; Knovich MA; Bayer RL; Schuster MW; Seiter K; Powell BL; Woodruff RD; Silver RT; Frankel AE; Feldman EJ
    Leuk Lymphoma; 2002 Oct; 43(10):1951-5. PubMed ID: 12481890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes.
    Giles FJ; Stopeck AT; Silverman LR; Lancet JE; Cooper MA; Hannah AL; Cherrington JM; O'Farrell AM; Yuen HA; Louie SG; Hong W; Cortes JE; Verstovsek S; Albitar M; O'Brien SM; Kantarjian HM; Karp JE
    Blood; 2003 Aug; 102(3):795-801. PubMed ID: 12649163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias.
    Lancet JE; Duong VH; Winton EF; Stuart RK; Burton M; Zhang S; Cubitt C; Blaskovich MA; Wright JJ; Sebti S; Sullivan DM
    Clin Cancer Res; 2011 Mar; 17(5):1140-6. PubMed ID: 21233404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial.
    Luger SM; Wang VX; Rowe JM; Litzow MR; Paietta E; Ketterling RP; Lazarus H; Rybka WB; Craig MD; Karp J; Cooper BW; Makary AZ; Kaminer LS; Appelbaum FR; Larson RA; Tallman MS
    Leuk Res; 2021 Dec; 111():106736. PubMed ID: 34773794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia.
    Kindler T; Breitenbuecher F; Marx A; Beck J; Hess G; Weinkauf B; Duyster J; Peschel C; Kirkpatrick CJ; Theobald M; Gschaidmeier H; Huber C; Fischer T
    Blood; 2004 May; 103(10):3644-54. PubMed ID: 14726395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas.
    Witzig TE; Tang H; Micallef IN; Ansell SM; Link BK; Inwards DJ; Porrata LF; Johnston PB; Colgan JP; Markovic SN; Nowakowski GS; Thompson CA; Allmer C; Maurer MJ; Gupta M; Weiner G; Hohl R; Kurtin PJ; Ding H; Loegering D; Schneider P; Peterson K; Habermann TM; Kaufmann SH
    Blood; 2011 Nov; 118(18):4882-9. PubMed ID: 21725056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia.
    Raponi M; Lancet JE; Fan H; Dossey L; Lee G; Gojo I; Feldman EJ; Gotlib J; Morris LE; Greenberg PL; Wright JJ; Harousseau JL; Löwenberg B; Stone RM; De Porre P; Wang Y; Karp JE
    Blood; 2008 Mar; 111(5):2589-96. PubMed ID: 18160667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase II randomized trial.
    Belhabri A; Thomas X; Wattel E; Chelghoum Y; Anglaret B; Vekhoff A; Reman O; Dombret H; Dhedin N; Michallet M; Fière D; Archimbaud E
    Hematol J; 2002; 3(1):49-55. PubMed ID: 11960396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome.
    Fenaux P; Raza A; Mufti GJ; Aul C; Germing U; Kantarjian H; Cripe L; Kerstens R; De Porre P; Kurzrock R
    Blood; 2007 May; 109(10):4158-63. PubMed ID: 17264294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d'Etude des Lymphomes de l'Adulte trial.
    Rolland D; Ribrag V; Haioun C; Ghesquieres H; Jardin F; Bouabdallah R; Franchi P; Briere J; De Kerviler E; Chassagne-Clement C; Raponi M; Houlgatte R; Jais JP; Thieblemont C
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):781-90. PubMed ID: 19960345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.